Dabigatran v warfarin: Compare with higher standard

BMJ (Online)

Volumn 341, Issue 7779, 2010, Pages 904-

  Edwards, Duncan ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DABIGATRAN; WARFARIN; ANTICOAGULANT AGENT; BENZIMIDAZOLE DERIVATIVE; DABIGATRAN ETEXILATE; PYRIDINE DERIVATIVE;

ANTICOAGULATION; DRUG EFFICACY; DRUG SAFETY; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LETTER; PRIORITY JOURNAL; NOTE; STANDARD; STROKE;

ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; HUMANS; INTERNATIONAL NORMALIZED RATIO; PYRIDINES; STROKE; WARFARIN;

EID: 78049471917     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.c5984     Document Type: Letter

References (3)

1. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51. [CrossRef] [Medline]
2. Raju NC, Hankey GJ. Dabigatran etexilate in people with atrial fibrillation. BMJ 2010;341:682-3. (29 July.)
3. Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010;376:975-83. [CrossRef] [Medline] [Web of Science]